- Home
- WFG vs APGE Comparison
WFG vs APGE Comparison
Compare WFG & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFG | APGE |
|---|---|---|
| Founded | 1955 | 2022 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.7B |
| IPO Year | 2007 | 2023 |
Fundamental Metrics
Financial Performance| Metric | WFG | APGE |
|---|---|---|
| Price | $65.10 | $72.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $89.50 | ★ $102.40 |
| AVG Volume (30 Days) | 215.6K | ★ 799.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.36 | N/A |
| Revenue Next Year | $10.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.34 | $26.20 |
| 52 Week High | $79.33 | $84.56 |
Technical Indicators
Market Signals| Indicator | WFG | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 39.31 | 55.03 |
| Support Level | $58.30 | $35.24 |
| Resistance Level | $76.53 | $82.77 |
| Average True Range (ATR) | 2.13 | 3.57 |
| MACD | -0.59 | 0.60 |
| Stochastic Oscillator | 25.05 | 79.23 |
Price Performance
Historical ComparisonAbout WFG West Fraser Timber Co. Ltd.
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.